News
PHVS
34.01
+2.13%
0.71
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
TipRanks · 7h ago
Pharvaris shareholders adopt Dutch statutory annual accounts for FY2025
PUBT · 8h ago
Robust RAPIDe-3 Deucrictibant Data Might Change The Case For Investing In Pharvaris (PHVS)
Simply Wall St · 17h ago
Pharvaris Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46
Benzinga · 1d ago
Analyst Reiterates Buy on Deucrictibant’s Strong HAE Profile and Lifts Price Target to $46
TipRanks · 1d ago
Pharvaris price target raised to $46 from $41 at Morgan Stanley
TipRanks · 1d ago
Pharvaris CMO Lu Peng disposes of 300 shares worth $10,200
PUBT · 3d ago
Weekly Report: what happened at PHVS last week (0615-0619)?
Weekly Report · 4d ago
Pharvaris (PHVS) Is Up 6.0% After Strong Phase 3 Oral HAE Data With Novel Endpoint Introduction
Simply Wall St · 06/18 18:26
Pharvaris (PHVS) Stock Could Be Far Below Fair Value After Phase 3 HAE Data
Simply Wall St · 06/16 11:29
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Pharvaris (PHVS)
TipRanks · 06/16 10:10
Analysts Are Bullish on Top Healthcare Stocks: Incyte (INCY), Pharvaris (PHVS)
TipRanks · 06/15 13:10
Pharvaris Highlights New Deucrictibant Data at EAACI 2026, Says HAE Treatment Data Support On-Demand and Preventive Use
Benzinga · 06/15 10:52
Pharvaris says Phase 3 RAPIDe-3 trial shows oral deucrictibant cuts median HAE symptom relief time to 1.28 hours
PUBT · 06/15 10:50
Weekly Report: what happened at PHVS last week (0608-0612)?
Weekly Report · 06/15 09:03
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
Barchart · 06/15 05:50
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
TipRanks · 06/11 20:15
Pharvaris publishes patient-reported outcomes presentation on clinical evidence in HAE trials
PUBT · 06/11 18:11
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance
TipRanks · 06/11 11:19
More
Webull provides a variety of real-time PHVS stock news. You can receive the latest news about Pharvaris N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.